Indian Regulators Crack Down: Strict GMP Compliance Required by Year End

As a clinician, the latest move from drug regulators raises both concern and hope. The DCGI has issued a final directive: all pharma manufacturing plants must fully comply with updated Good Manufacturing Practice (GMP) rules by 31 December 2025, or face closure.

Why this matters to us doctors:

• It’s a reassurance for patient safety — enforcing GMP means fewer chances of sub-standard or contaminated drugs entering the market.

• Many smaller pharma firms (MSMEs) are under stricter scrutiny now.

• In the short term, this could tighten supplies if non-compliant plants shut down — something we may need to plan around in our prescriptions.

• In the long run, this should strengthen the credibility of Indian-made medicines globally, which is a win for both patients and prescribers.